|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
To further test if this locus is associated with tobacco smoking as measured by numCIG and FTND, we conducted replication and meta-analysis in 12 independent samples (n>16,000) for two markers in ACSL6 reported in our previous schizophrenia study.
|
22205969 |
2011 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
Further analysis using haplotypes demonstrated that a haplotype block spanning PDZ-GEF2, LOC728637 and ACSL6 is highly associated with schizophrenia and several haplotypes in this haploblock have about twofold to 10-fold increase in the affected subjects.
|
18718982 |
2008 |
|
Schizophrenia
|
0.340 |
GeneticVariation
|
disease |
LHGDN |
Further analysis using haplotypes demonstrated that a haplotype block spanning PDZ-GEF2, LOC728637 and ACSL6 is highly associated with schizophrenia and several haplotypes in this haploblock have about twofold to 10-fold increase in the affected subjects.
|
18718982 |
2008 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
PSYGENET |
Further analysis using haplotypes demonstrated that a haplotype block spanning PDZ-GEF2, LOC728637 and ACSL6 is highly associated with schizophrenia and several haplotypes in this haploblock have about twofold to 10-fold increase in the affected subjects.
|
18718982 |
2008 |
|
Schizophrenia
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Using a rapid, efficient strategy designed to investigate all common SNPs, we tested associations between schizophrenia and two positional candidate genes: ACSL6 (Acyl-Coenzyme A synthetase long-chain family member 6) and SIRT5 (silent mating type information regulation 2 homologue 5).
|
16827919 |
2007 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
PSYGENET |
Using a rapid, efficient strategy designed to investigate all common SNPs, we tested associations between schizophrenia and two positional candidate genes: ACSL6 (Acyl-Coenzyme A synthetase long-chain family member 6) and SIRT5 (silent mating type information regulation 2 homologue 5).
|
16827919 |
2007 |
|
Schizophrenia
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
From these data, we concluded that haplotypes underlying the SPEC2/PDZ-GEF2/ACSL6 region are associated with schizophrenia.
|
17030554 |
2006 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
PSYGENET |
From these data, we concluded that haplotypes underlying the SPEC2/PDZ-GEF2/ACSL6 region are associated with schizophrenia.
|
17030554 |
2006 |
|
Schizophrenia
|
0.340 |
GeneticVariation
|
disease |
LHGDN |
From these data, we concluded that haplotypes underlying the SPEC2/PDZ-GEF2/ACSL6 region are associated with schizophrenia.
|
17030554 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.320 |
Biomarker
|
disease |
BEFREE |
Low ACSL6 predicted a worse prognosis in acute myeloid leukemia.
|
27171439 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.320 |
Biomarker
|
disease |
BEFREE |
The resulting ETV6/ACS2 fusion transcripts showed an out-frame fusion of exon 1 of ETV6 to exon 1 of ACS2 in the AEL case, an out-frame fusion of exon 1 of ETV6 to exon 11 of ACS2 in the AML case, and a short in-frame fusion of ETV6 exon 1 to the 3' untranslated region of ACS2 in the RAEB case.
|
10502316 |
1999 |
|
Leukemia, Myelocytic, Acute
|
0.320 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Schizoaffective Disorder
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Using pooled DNA samples from cases with schizophrenia/schizoaffective disorder (Diagnostic and Statistical Manual of Mental Disorders edition IV criteria) and controls (n=200, each group), we next sequenced all exons, introns and flanking upstream/downstream sequences for ACSL6 and SIRT5.
|
16827919 |
2007 |
|
MYELODYSPLASTIC SYNDROME
|
0.310 |
GeneticVariation
|
group |
BEFREE |
Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13).
|
10502316 |
1999 |
|
MYELODYSPLASTIC SYNDROME
|
0.310 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
|
Amphetamine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome-wide association for methamphetamine dependence: convergent results from 2 samples.
|
18316681 |
2008 |
|
Amphetamine Addiction
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association for methamphetamine dependence: convergent results from 2 samples.
|
18316681 |
2008 |
|
Amphetamine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association for methamphetamine dependence: convergent results from 2 samples.
|
18316681 |
2008 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin.
|
16428347 |
2006 |
|
Inflammation
|
0.200 |
Biomarker
|
phenotype |
RGD |
Up-regulation of fatty acid metabolizing-enzymes mRNA in rat spinal cord during persistent peripheral local inflammation.
|
14622223 |
2003 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A novel Alzheimer disease locus located near the gene encoding tau protein.
|
25778476 |
2016 |
|
Myocardial Infarction
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Evidence from Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51 (ATLAS-ACS 2-TIMI 51) supports the use of the direct, oral, factor Xa inhibitor rivaroxaban (2.5 mg twice-daily [bid] and 5 mg bid) in reducing mortality and morbidity in patients with acute coronary syndrome, when combined with antiplatelets.
|
29566413 |
2018 |
|
Myocardial Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
ATLAS-ACS-2 Thrombolysis in Myocardial Infarction-51 was a double-blind, multicenter, phase 3 clinical trial that randomized patients within 7 days of an ACS event to standard of care plus either rivaroxaban 2.5 mg BID, 5 mg BID, or placebo (n = 15,526).
|
30340765 |
2018 |
|
Acute Coronary Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
|
30340765 |
2018 |
|
Acute Coronary Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Evidence from Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51 (ATLAS-ACS 2-TIMI 51) supports the use of the direct, oral, factor Xa inhibitor rivaroxaban (2.5 mg twice-daily [bid] and 5 mg bid) in reducing mortality and morbidity in patients with acute coronary syndrome, when combined with antiplatelets.
|
29566413 |
2018 |